NEW YORK , Nov. 7, 2024 /PRNewswire/ -- Report with the AI impact on market trends - The acute myeloid leukemia (AML) treatment market in APAC size is estimated to grow by USD 305.8 million from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 13.9% during the forecast period. High incidence of acute myeloid leukemia is driving market growth, with a trend towards car t-cell therapy for AML.
However, lack of adequate healthcare infrastructure in developing nations poses a challenge.Key market players include AbbVie Inc., Agios Inc.
, Amgen Inc., Astellas Pharma Inc., Astex Pharmaceuticals Inc.
, Bristol Myers Squibb Co., CTI BioPharma Corp., Cyclacel Pharmaceuticals, Inc.
, Daiichi Sankyo Co. Ltd., F.
Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Jazz Pharmaceuticals Plc, Johnson and Johnson Services Inc., MEI Pharma Inc, Novartis AG, Pfizer Inc.
, and Teva Pharmaceutical Industries Ltd.. AI-Powered Market Evolution Insights.
Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View Free Sample Report PDF CAR T-cell therapy holds potential in treating Acute Myeloid Leukemia (AML), but faces challenges due to the difficulty of identifying specific antigens on AML cells without affecting healthy hematopoietic stem cells and the immunosuppressive tumor microenvironment. Innovations target multiple antigens like ADGRE2 and CLEC12A, and combining CAR T-cell therapy with existing drugs, such as azacitid.
